CFGI’s Capital Markets and Accounting Advisory teams assisted enGene Holdings Inc. (“enGene” or the “Company,”) (NASDAQ: ENGN) in completing the previously announced business combination between enGene Inc., a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company. The business combination was structured as a reverse recapitalization.
enGene will commence trading under the symbol “ENGN” on November 1, 2023, on Nasdaq.
enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is EG-70 for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. EG-70 is being evaluated in an ongoing Phase 2 pivotal study. EG-70 was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
The CFGI Capital Markets team was led by Carla Amaning, Chris Brandes, and Yachen Suvorov, and the Accounting Advisory team was led by Keith Ouellette and Daniel Sawicki. For further information on the transaction, please read enGene’s press release.
